Evidence map›Paper›PMID 41373608›Full record

ArticleInternational journal of molecular sciences2025

Computational Phenotypic Drug Discovery for Anticancer Chemotherapy: PTML Modeling of Multi-Cell Inhibitors of Colorectal Cancer Cell Lines.

Alejandro Speck-Planche, M Natália D S Cordeiro

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alejandro Speck-PlancheLAQV/REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, 4169-007 Porto, Portugal.ORCID 0000-0002-9544-9016
M Natália D S CordeiroLAQV/REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, 4169-007 Porto, Portugal.ORCID 0000-0003-3375-8670

Funding

FCT/MCTES, Fundação para a Ciência e Tecnologia, and Ministério da Ciência, Tecnologia e Ensino Superior UID/50006 - Laboratório Associado para a Química Verde - Tecnologias e Processos Limpos
6 · The paper itself

Abstract

Colorectal cancer is one of the most dangerous neoplastic diseases in terms of both mortality and incidence. Thus, anti-colorectal cancer agents are urgently needed. Computational approaches have great potential to accelerate the phenotypic discovery of versatile anticancer agents. Here, by combining perturbation-theory machine learning (PTML) modeling with the fragment-based topological design (FBTD) approach, we provide key computational evidence on the computer-aided de novo design and prediction of new molecules virtually exhibiting multi-cell inhibitory activity against different colorectal cancer cell lines. The PTML model created in this study achieved sensitivity and specificity values exceeding 80% in training and test sets. The FBTD approach was employed to physicochemically and structurally interpret the PTML model. These interpretations enabled the rational design of six new drug-like molecules, which were predicted as active against multiple colorectal cancer cell lines by both our PTML model and a CLC-Pred 2.0 webserver, with the latter being a well-established virtual screening tool for early anticancer discovery. This work confirms the potential of the joint use of PTML and FBTD as a unified computational methodology for early phenotypic anticancer drug discovery.

Indexed as

Antineoplastic AgentsColorectal NeoplasmsDrug DiscoveryMachine LearningCell Line, TumorHumansPhenotypeAntineoplastic Agentscolorectal cancerfragmentfragment-based topological designmultilayer perceptronPTMLtopological indices

Identifiers

PMID41373608
PMCPMC12692404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.